Pluristem Therapeutics, Inc. (NASDAQ:PSTI) is set to release its earnings data after the market closes on Monday, November 13th. Analysts expect Pluristem Therapeutics to post earnings of ($0.08) per share for the quarter.

Shares of Pluristem Therapeutics, Inc. (NASDAQ PSTI) opened at $1.65 on Monday. Pluristem Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $2.12.

ILLEGAL ACTIVITY WARNING: “Pluristem Therapeutics, Inc. (PSTI) to Release Earnings on Monday” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/pluristem-therapeutics-inc-psti-to-release-earnings-on-monday/1682296.html.

Several research firms have weighed in on PSTI. Maxim Group set a $2.00 target price on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 16th. HC Wainwright reiterated a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a report on Wednesday, September 6th. ValuEngine lowered shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research lowered shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $4.38.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.